TNXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tonix Pharmaceuticals (TNXP) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite some positive catalysts like FDA approval for Tonmya and uplisting to Nasdaq, the technical indicators are bearish, and the financial performance shows significant losses. The options data suggests low trading sentiment, and there are no strong proprietary trading signals to support a buy decision. Holding off on investing in TNXP until further positive developments or improved financial performance would be prudent.
The technical indicators for TNXP are bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 24.647, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock price is near its support level (S1: 13.316), with resistance levels at R1: 14.814 and R2: 15.276.
FDA approval for Tonmya as a treatment for fibromyalgia, which enhances patient treatment options and could drive future revenue growth.
Uplisting to the Nasdaq Global Select Market, which may improve visibility and liquidity among investors.
The stock price has declined post-uplisting, indicating weak investor sentiment.
The company's financials show significant losses, with a net income of -$32 million and a declining EPS of -3.59 in Q3 2025.
In Q3 2025, revenue increased by 16.58% YoY to $3.29 million, and gross margin improved to 58.45% (up 30.18% YoY). However, the company reported a net loss of $32.01 million (up 125.22% YoY), and EPS dropped significantly to -3.59 (-84.31% YoY).
No analyst rating or price target data is provided for TNXP.
